Abstract
Retinoic acid (RA)-metabolizing enzyme CYP26A1 has been shown to have increased expression levels in breast cancers and to effectively promote the survival of breast carcinoma cells, implying a potential oncogenic function. However, the expression of CYP26C1, another CYP26 family member, in primary breast carcinoma remains to be clarified. In the present study, we examined the expression of CYP26C1 by immunohistochemistry, using three different types of microarray, and observed strong cytoplasmic staining of CYP26C1 in 73 of the 219 (33.3 %) breast carcinomas. In contrast, CYP26C1 was not expressed in normal ductal and lobular cells in non-neoplastic tissue. Interestingly, increased expression of CYP26C1 was significantly associated with a high Ki-67 labeling index and a grade of tumor. However, CYP26C1 immunoreactivity was not associated with clinicopathological variables, including primary tumor status, lymph node involvement, distant metastasis, and tumor stage. In addition, CYP26C1 positivity was independent of the expression status of the hormone receptors and immunohistochemical surrogates for the intrinsic subtypes of breast cancer. This report is the first to demonstrate elevated expression of CYP26C1 in primary breast carcinomas. Based on the RA-catabolizing activity of CYP26C1, our data suggest that CYP26C1 expression may contribute to neoplasia in the breast.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ross AC, Zolfaghari R (2011) Cytochrome P450s in the regulation of cellular retinoic acid metabolism. Annu Rev Nutr 31:65–97
Osanai M, Sawada N, Lee GH (2010) Oncogenic and cell survival properties of the retinoic acid metabolizing enzyme, CYP26A1. Oncogene 29:1135–1144
Chang CL, Hong E, Lao-Sirieix P, Fitzgerald RC (2008) A novel role for the retinoic acid-catabolizing enzyme CYP26A1 in Barrett’s associated adenocarcinoma. Oncogene 27:2951–2960
Shelton DN, Sandoval IT, Eisinger A, Chidester S, Ratnayake A, Ireland CM, Jones DA (2006) Up-regulation of CYP26A1 in adenomatous polyposis coli-deficient vertebrates via a WNT-dependent mechanism: implications for intestinal cell differentiation and colon tumor development. Cancer Res 66:7571–7577
Sonneveld E, van den Brink CE, van der Leede BM, Schulkes RK, Petkovich M, van der Burg B, van der Saag PT (1998) Human retinoic acid (RA) 4-hydroxylase (CYP26) is highly specific for all-trans-RA and can be induced through RA receptors in human breast and colon carcinoma cells. Cell Growth Diff 9:629–637
Osanai M, Lee GH (2014) Increased expression of the retinoic acid-metabolizing enzyme CYP26A1 during the progression of cervical squamous neoplasia and head and neck cancer. BMC Res Notes 7:697
Taimi M, Helvig C, Wisniewski J, Ramshaw H, White J, Amad M, Korczak B, Petkovich M (2004) A novel cytochrome P450, CYP26C1, involved in metabolism of 9-cis and all-trans isomers of retinoic acid. J Biol Chem 279:77–85
Brown G, Cash BG, Blihoghe D, Johansson P, Alnabulsi A, Murray GI (2014) The expression and prognostic significance of retinoic acid metabolizing enzymes in colorectal cancer. PLoS One 9:e90776
Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19:403–410
American Joint Committee on Cancer (2010) AJCC cancer staging manual, 7th edn. Springer, New York
Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van der Vijver MJ (2012) WHO classification of tumours of the breast, 4th edn. International Agency for Research on Cancer, Lyon
Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ, Panel members (2011) Strategies for subtypes–dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22:1736–1747
Garattini E, Bolis M, Garattini SK, Fratelli M, Centritto F, Paroni G, Gianni M, Zanetti A, Pagani A, Fisher JN, Zambell A, Terao M (2014) Retinoids and breast cancer: from basic studies to the clinic and back again. Cancer Treat Rev 40:739–749
Cornic M, Agadir A, Degos L, Chomienne C (1994) Retinoids and differentiation treatment: a strategy for treatment in cancer. Anticancer Res 14:2339–2346
Wolbach SB, Howe PR (1925) Tissue changes following deprivation of fat-soluble A vitamin. J Exp Med 43:753–777
Wang Z, Boudjelal M, Kang S, Voorhees JJ, Fisher GJ (1999) Ultraviolet irradiation of human skin causes functional vitamin A deficiency, preventable by all-trans retinoic acid pre-treatment. Nat Med 5:418–422
French AL, Kirstein LM, Massad LS, Semba RD, Minkoff H, Landesman S, Palefsky J, Young M, Anastos K, Cohen MH (2000) Association of vitamin A deficiency with cervical squamous intraepithelial lesions in human immunodeficiency virus-infected women. J Infect Dis 182:1084–1089
Acknowledgments
This study was supported in part by grants from the Grants-in-Aid for Scientific Research program of the Japan Society for the Promotion of Science.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Osanai, M., Lee, GH. Elevated expression of the retinoic acid-metabolizing enzyme CYP26C1 in primary breast carcinomas. Med Mol Morphol 49, 22–27 (2016). https://doi.org/10.1007/s00795-015-0110-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00795-015-0110-7